Bristol Myers joins in vivo CAR-T race with $1.5B Orbital acquisition

Bristol Myers Squibb is delving further into cell therapies with the $1.5 billion cash purchase of Orbital Therapeutics, the New Jersey pharma said Friday morning. The move positions BMS in the ...